Business
IGC Pharma Expands Phase 2 CALMA Clinical Trial to University of South Florida's Department of Psychiatry and Behavioral Neurosciences
POTOMAC, MD / ACCESS Newswire / October 14, 2025 / IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC), a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's disease, today announced ...
About this update from Igc Pharma, Inc.
[{"type":"text","content":"POTOMAC, MD / ACCESS Newswire / October 14, 2025 / IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC), a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's disease, today announced the expansion of its ongoing Phase 2 CALMA clinical trial evaluating investigational drug candidate IGC-AD1 for agitation in Alzheimer's disease. The trial has officially opened a new site at the University of South Florida's Department of Psychiatry and Behavioral Neurosciences, under the leadership of Principal Investigator Dr. Ram Bishnoi.","length":642,"tagName":"p"},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":"IGC Pharma, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":1504,"height":890,"url":"https://media.zenfs.com/en/accesswire.ca/1da758016321be8ee541aadc028a3e79"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ca8iN1qgGyL3rv8bBhKjHA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU2ODtjZj13ZWJw/https://media.zenfs.com/en/accesswire.ca/1da758016321be8ee541aadc028a3e79","width":960,"height":568},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/nKiDQ8vEZa0w.6CXIb1nVA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0xNDIwO2NmPXdlYnA-/https://media.zenfs.com/en/accesswire.ca/1da758016321be8ee541aadc028a3e79","width":1200,"height":710}},"href":"https://app.accessnewswire.com/imagelibrary/df1b42d3-457c-4d9f-b18c-e557122e7e32/1086610/igc-pharma-inc-2025.png","hrefExternal":true},{"type":"text","content":"Enrollment at the new site has already begun, with four participants enrolled, marking an important step toward accelerating recruitment and advancing the timeline of the study. The addition of USF, a leading research and academic institution, underscores IGC Pharma's commitment to partnering with distinguished investigators to address the urgent, unmet needs of patients living with Alzheimer's disease.","length":414,"tagName":"p"},{"type":"text","content":""The opening of this site at the University of South Florida strengthens our ability to recruit diverse participants while ensuring the highest standard of clinical oversight," said Ram Mukunda, CEO of IGC Pharma. "USF brings a strong academic pedigree, deep expertise in behavioral neuroscience, and an establis...